WallStSmart

Alcon AG (ALC)vsHarvard Bioscience Inc (HBIO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 11917% more annual revenue ($10.40B vs $86.55M). ALC leads profitability with a 9.4% profit margin vs -65.5%. HBIO appears more attractively valued with a PEG of 1.31. ALC earns a higher WallStSmart Score of 49/100 (D+).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 7.3Quality: 7.3
Piotroski: 4/9

HBIO

Avoid

30

out of 100

Grade: F

Growth: 2.0Profit: 3.5Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-489.8%)

Margin of Safety

-489.8%

Fair Value

$13.46

Current Price

$75.26

$61.80 premium

UndervaluedFair: $13.46Overvalued

Intrinsic value data unavailable for HBIO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

HBIO1 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

EPS GrowthGrowth
-22.2%2/10

Earnings declined 22.2%

HBIO4 concerns · Avg: 2.3/10
Market CapQuality
$235.92M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-147.1%2/10

ROE of -147.1% — below average capital efficiency

Revenue GrowthGrowth
-3.3%2/10

Revenue declined 3.3%

EPS GrowthGrowth
-80.3%2/10

Earnings declined 80.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Debt/Equity, Price/Book.

Bull Case : HBIO

The strongest argument for HBIO centers on Price/Book. PEG of 1.31 suggests the stock is reasonably priced for its growth.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, P/E Ratio, Return on Equity.

Bear Case : HBIO

The primary concerns for HBIO are Market Cap, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

ALC profiles as a value stock while HBIO is a turnaround play — different risk/reward profiles.

HBIO carries more volatility with a beta of 1.45 — expect wider price swings.

ALC is growing revenue faster at 8.6% — sustainability is the question.

ALC generates stronger free cash flow (489M), providing more financial flexibility.

Bottom Line

ALC scores higher overall (49/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Harvard Bioscience Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.

Want to dig deeper into these stocks?